Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Suprefact, Suprecur

Buserelin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Buserelin (also known as Suprefact) is a peptide catalogued under Sexual Health (GnRH agonist). It is described as: GnRH receptor agonist. Documented context: Prostate cancer; endometriosis. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Buserelin?

Buserelin (brand name Suprefact) is a synthetic gonadotropin-releasing hormone (GnRH) agonist analog used to suppress sex-steroid production.

It is approved in the EU, UK and Canada for advanced prostate cancer, endometriosis and controlled ovarian stimulation in IVF/assisted reproduction, but it is not FDA-approved in the United States.

Human evidence is substantial, including randomized controlled trials in endometriosis and prostate cancer and large IVF cohort studies.

How does Buserelin work?

Buserelin initially stimulates pituitary GnRH receptors, causing a transient surge (flare) in LH, FSH and consequently testosterone or estradiol.

With continuous administration the pituitary desensitizes and downregulates, producing sustained suppression of LH/FSH and sex steroids to castrate/menopausal levels.

What does the research say about Buserelin?

  • In endometriosis, buserelin reduces implants and pelvic pain comparably to danazol in randomized comparison. [2]
  • In assisted reproduction, GnRH-agonist down-regulation regimens with buserelin support cumulative conception and live-birth outcomes in IVF. [3]
  • In advanced prostate cancer, buserelin achieves androgen suppression and is used within maximal androgen blockade regimens. [4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile — Brogden RN et al., Drugs 1990. (Narrative pharmacology review)
  • [2] Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study — Dmowski WP et al., Fertility and Sterility 1989. (Randomized controlled trial)
  • [3] Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin — Tan SL et al., American Journal of Obstetrics and Gynecology 1994. (Large cohort/comparative study)
  • [4] Maximum androgen blockade using LHRH agonist buserelin in combination with short-term or long-term cyproterone acetate in advanced prostate cancer treatment — de Voogt HJ et al., European Urology 1998. (Randomized controlled trial)
  • [5] Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol — Trabant H et al., Progress in Clinical and Biological Research 1990. (Pooled clinical-trial review)
  • [6] Buserelin in the treatment of prostatic cancer — Roila F et al., Biomedicine and Pharmacotherapy 1989. (Clinical review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Buserelin has historically been given by subcutaneous injection or intranasal spray, with formulation and schedule set by the treating specialist for the specific indication.

Dosing is strictly a clinician-directed medical decision and this information is contextual, not a protocol.

Side effects & safety profile

Because of the initial agonist flare, testosterone or estrogen rises transiently at the start of therapy, which can briefly worsen prostate-cancer symptoms (a reason anti-androgen cover is used).

Class effects include hot flushes and other vasomotor symptoms from hypoestrogenism/hypoandrogenism.

Prolonged suppression causes loss of bone mineral density, so treatment duration is limited or add-back therapy is considered.

Stacking & combinations

In clinical use it is combined only under medical supervision, for example with an anti-androgen at initiation in prostate cancer or with estrogen/progestin add-back in endometriosis; it is not a compound for self-directed combination.

Finding Buserelin vendors

Finding Buserelin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

No. Buserelin (Suprefact) is approved in the EU, UK and Canada for prostate cancer, endometriosis and IVF down-regulation, but it is not FDA-approved in the US.

References

  1. [1] Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile — Brogden RN et al., Drugs 1990. PMID: 2109679. View sourceStudy: Narrative pharmacology reviewSummarizes buserelin's GnRH-agonist pharmacology and clinical profile across prostate cancer, endometriosis and reproductive indications.
  2. [2] Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study — Dmowski WP et al., Fertility and Sterility 1989. PMID: 2493400. View sourceStudy: Randomized controlled trialBuserelin produced ovarian suppression and endometriosis improvement comparable to danazol with a different side-effect profile.
  3. [3] Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin — Tan SL et al., American Journal of Obstetrics and Gynecology 1994. PMID: 8059833. View sourceStudy: Large cohort/comparative studyGnRH-agonist (buserelin) down-regulation, especially long regimens, improved cumulative conception and live-birth rates in IVF.
  4. [4] Maximum androgen blockade using LHRH agonist buserelin in combination with short-term or long-term cyproterone acetate in advanced prostate cancer treatment — de Voogt HJ et al., European Urology 1998. PMID: 9519356. View sourceStudy: Randomized controlled trialBuserelin with cyproterone acetate provided effective androgen blockade in advanced prostate cancer.
  5. [5] Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol — Trabant H et al., Progress in Clinical and Biological Research 1990. PMID: 2106146. View sourceStudy: Pooled clinical-trial reviewIntranasal buserelin was effective and safe for endometriosis across six trials, comparable to danazol.
  6. [6] Buserelin in the treatment of prostatic cancer — Roila F et al., Biomedicine and Pharmacotherapy 1989. PMID: 2506941. View sourceStudy: Clinical reviewBuserelin achieves medical castration and is an alternative to orchiectomy/estrogens in advanced prostate cancer.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.